Work

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

Year: 2017

Type: review

Source: Cancer Treatment Reviews

DOI: 10.1016/j.ctrv.2017.05.003

Authors: Jessica C. Hassel, Lucie Heinzerling, Jens Aberle, Oliver Bähr, Thomas K. Eigentler, Marc-Oliver Grimm, Victor Grünwald, Jan Leipe, Niels Reinmuth, Julia K. Tietze, Jörg Trojan, Lisa Zimmer, Ralf Gutzmer

Institutions: University Hospital Heidelberg, Universitätsklinikum Erlangen, University Medical Center Hamburg-Eppendorf, University Hospital Frankfurt, Universitätsklinikum Tübingen, Jena University Hospital, Medizinische Hochschule Hannover, Ludwig-Maximilians-Universität München, Asklepios Fachkliniken München-Gauting, LMU Klinikum, Essen University Hospital, University of Duisburg-Essen

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Pfizer, Sanofi, Les Laboratories Pierre Fabre, Sanofi Genzyme

OpenAlex ID: W2614467908

FWCI: 4.742

Cites: 119

Cited by: 337

Related to: 10